INTRODUCTION: Proton magnetic resonance spectroscopy (¹H MRS) enables the evaluation of in vivo brain function. The purpose of the study was to compare ¹H MRS measurements in schizophrenic patients, who were clinical responders after short-term antipsychotic treatment, with non-responders and healthy controls. METHODS: We investigated a group of 47 patients diagnosed with schizophrenia. Patients were examined twice--once after a period of at least 7 days without neuroleptics and the second time at least 4 weeks after therapy with stable doses of medication. The follow-up was available in 42 patients. Baseline MRS measurements of clinical responders were compared with non-responders and the group of healthy controls (N=26). We assessed the following metabolite ratios: NAA (N-acetylaspartate), Glx (complex of GABA, glutamine and glutamate), Cho (choline) and mI (myo-inositol) to creatinine (Cr) in the left frontal and temporal lobes and the thalamus. RESULTS: Responders showed a significantly lower baseline frontal Glx/Cr level than non-responders. Both groups had a significantly lower NAA/Cr ratio in the frontal lobe than the controls, but only non-responders had a significantly lower NAA/Cr ratio in the thalamus. CONCLUSIONS: Our results confirm the relationship between the glutamatergic system and pathophysiology of schizophrenia and suggest a significant value of ¹H MRS examination in the assessment of the future treatment effect.
INTRODUCTION: Proton magnetic resonance spectroscopy (¹H MRS) enables the evaluation of in vivo brain function. The purpose of the study was to compare ¹H MRS measurements in schizophrenicpatients, who were clinical responders after short-term antipsychotic treatment, with non-responders and healthy controls. METHODS: We investigated a group of 47 patients diagnosed with schizophrenia. Patients were examined twice--once after a period of at least 7 days without neuroleptics and the second time at least 4 weeks after therapy with stable doses of medication. The follow-up was available in 42 patients. Baseline MRS measurements of clinical responders were compared with non-responders and the group of healthy controls (N=26). We assessed the following metabolite ratios: NAA (N-acetylaspartate), Glx (complex of GABA, glutamine and glutamate), Cho (choline) and mI (myo-inositol) to creatinine (Cr) in the left frontal and temporal lobes and the thalamus. RESULTS: Responders showed a significantly lower baseline frontal Glx/Cr level than non-responders. Both groups had a significantly lower NAA/Cr ratio in the frontal lobe than the controls, but only non-responders had a significantly lower NAA/Cr ratio in the thalamus. CONCLUSIONS: Our results confirm the relationship between the glutamatergic system and pathophysiology of schizophrenia and suggest a significant value of ¹H MRS examination in the assessment of the future treatment effect.
Authors: Jennifer H Foss-Feig; Brendan D Adkinson; Jie Lisa Ji; Genevieve Yang; Vinod H Srihari; James C McPartland; John H Krystal; John D Murray; Alan Anticevic Journal: Biol Psychiatry Date: 2017-03-14 Impact factor: 13.382
Authors: Eline M P Poels; Lawrence S Kegeles; Joshua T Kantrowitz; Daniel C Javitt; Jeffrey A Lieberman; Anissa Abi-Dargham; Ragy R Girgis Journal: Schizophr Res Date: 2014-01-11 Impact factor: 4.939
Authors: Elias Mouchlianitis; Michael A P Bloomfield; Vincent Law; Katherine Beck; Sudhakar Selvaraj; Naresh Rasquinha; Adam Waldman; Federico E Turkheimer; Alice Egerton; James Stone; Oliver D Howes Journal: Schizophr Bull Date: 2015-12-17 Impact factor: 9.306
Authors: Anna Höflich; Andreas Hahn; Martin Küblböck; Georg S Kranz; Thomas Vanicek; Christian Windischberger; Alois Saria; Siegfried Kasper; Dietmar Winkler; Rupert Lanzenberger Journal: Int J Neuropsychopharmacol Date: 2015-04-19 Impact factor: 5.176
Authors: Michael A Hunter; Brian A Coffman; Charles Gasparovic; Vince D Calhoun; Michael C Trumbo; Vincent P Clark Journal: Brain Res Date: 2014-10-12 Impact factor: 3.252